Rossari Biotech Limited has reported consolidated financial results for the period ended March 31, 2025.

Rossari Biotech has posted net profit of Rs. 34.44 crores for the period ended March 31, 2025 as against net profit of Rs. 34.13 crores for the period ended March 31, 2024. The company posted net profit of Rs. 31.70 crores for the period ended December 31, 2024.

The company has reported total income of Rs. 581.35 crores during the period ended March 31, 2025 as compared to Rs.473.105 crores during the period ended March 31, 2024. The company reported total income of Rs. 513.282 crores during the period ended December 31, 2024.

For the Financial Year ended March 31, 2025, Rossari Biotech has reported total income of Rs. 2,084.30 crores as compared to Rs. 1,838 crores during the Financial Year ended March 31, 2024.

The company has posted net profit of Rs. 136.37 crores for the Financial Year ended March 31, 2025 as against net profit of Rs. 130.68 crores for the Financial Year ended March 31, 2024.

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said: “We concluded the year with a steady performance, navigating a soft and evolving operating environment. Revenues grew by ~14% driven by healthy export momentum and resilient volumes across key categories. The HPPC segment remained the primary growth driver, supported by deeper market penetration and strong traction across agrochemicals, personal care, institutional and consumer business. The TSC and AHN segments recorded modest revenue growth, contributing positively to the overall performance. We remain optimistic about their medium-to-long-term potential, supported by ongoing portfolio optimization efforts.

“Export markets continued to perform well during the year, validating our strategic investments in global partnerships and differentiated solutions. We are also encouraged by the growing momentum in emerging verticals such as institutional cleaning and B2C businesses, which reflect our ability to build scalable, value-added platforms aligned with evolving customer needs.

“We continue to invest in capacity enhancement to strengthen our growth foundation and are pleased to announce an additional capex of Rs. 97 crore for expansions at our subsidiaries, Unitop Chemicals and Tristar Intermediates, along with Rs. 95 crore at Rossari Biotech. These projects, expected to be commissioned in a phased manner by Q4 FY26, are aimed at supporting growth across our key chemistries, improving operational efficiency, and enhancing supply reliability. Our previously announced expansion projects are progressing well, with commissioning expected by Q2 FY26. With these capacity additions, we are well-positioned to meet growing demand across end-user industries.

“Looking ahead, we remain focused on delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, we are confident in our ability to maintain healthy growth momentum in the coming years.”